Senior Fitness - Exercise and Nutrition for Aging Men and Women
FREE Article Feed for your website.
Home Ownership Magazine
Party Planning Information
Article Marketing Resources
Bio-Medical Research Article Database
Informative Articles on Life, Love and Happiness
Tutorials on Business to Writing
Famous Quotes from Famous People
Song Lyric Information
New US Patent Information
Comprehensive List of Content by Category
Online Auctions and Shopping Related Articles
Article Search
Most Recent Articles
Title: Signal generating apparatus for a bicycle control device
Patent Number: 7,522,033 Issued on 04/21/2009 to Takamoto,   et al.

Title: Method for detecting decrease in inner pressure of tire using GPS speed information
Patent Number: 7,522,032 Issued on 04/21/2009 to Nakao

Title: Apparatus and method for controlling alarm by motion recognition in a portable terminal
Patent Number: 7,522,031 Issued on 04/21/2009 to Lim

Title: Starter relay
Patent Number: 7,522,030 Issued on 04/21/2009 to Kobayasi

Title: Phase change actuator
Patent Number: 7,522,029 Issued on 04/21/2009 to Lantz

Title: Magnetic element
Patent Number: 7,522,028 Issued on 04/21/2009 to Sano

Title: Magnet assembly and a method for constructing a magnet assembly
Patent Number: 7,522,027 Issued on 04/21/2009 to Calvert,   et al.

Title: Alignment method and system for electromagnet in high-energy accelerator
Patent Number: 7,522,026 Issued on 04/21/2009 to Kitahara,   et al.

Title: Switchgear with a switching device and an electronic component as well as a supplementary electrical circuit for the switchgear
Patent Number: 7,522,025 Issued on 04/21/2009 to Zeitlberger,   et al.

Title: Negative g.sub.m circuit, a filter and low noise amplifier including such a filter
Patent Number: 7,522,024 Issued on 04/21/2009 to Beffa

Title: Gyrator with feedback resistors
Patent Number: 7,522,023 Issued on 04/21/2009 to Chang,   et al.

Title: Planar filter, semiconductor device and radio unit
Patent Number: 7,522,022 Issued on 04/21/2009 to Yamada

Title: Surface acoustic wave apparatus
Patent Number: 7,522,021 Issued on 04/21/2009 to Wada,   et al.

Title: Boundary acoustic wave device and method for manufacturing boundary acoustic wave device
Patent Number: 7,522,020 Issued on 04/21/2009 to Kando

Title: Internal electrostatic transduction structures for bulk-mode micromechanical resonators
Patent Number: 7,522,019 Issued on 04/21/2009 to Bhave,   et al.

Title: Electro-acoustic resonator with a top electrode layer thinner than a bottom electrode layer
Patent Number: 7,522,018 Issued on 04/21/2009 to Milsom,   et al.

Title: High-Q integrated RF filters
Patent Number: 7,522,017 Issued on 04/21/2009 to Groe,   et al.

Title: Tunable surface acoustic wave resonators
Patent Number: 7,522,016 Issued on 04/21/2009 to Toncich,   et al.

Title: Switch circuit, front end module and radio terminal including switch circuit
Patent Number: 7,522,015 Issued on 04/21/2009 to Oikawa,   et al.

Title: High frequency line-to-waveguide converter and high frequency package
Patent Number: 7,522,014 Issued on 04/21/2009 to Koriyama

Title: Non-reciprocal circuit device
Patent Number: 7,522,013 Issued on 04/21/2009 to Kishimoto,   et al.

Title: Nonreciprocal circuit device and manufacturing method of the same
Patent Number: 7,522,012 Issued on 04/21/2009 to Wada

Title: High pass modulation of a phase locked loop
Patent Number: 7,522,011 Issued on 04/21/2009 to Matero,   et al.

Title: Ultra-low power crystal oscillator
Patent Number: 7,522,010 Issued on 04/21/2009 to Liang,   et al.

Title: Oscillation stabilization circuit
Patent Number: 7,522,009 Issued on 04/21/2009 to Kwon,   et al.

Title: Injection locker frequency divider
Patent Number: 7,522,008 Issued on 04/21/2009 to Jang,   et al.

Title: Injection locked frequency divider
Patent Number: 7,522,007 Issued on 04/21/2009 to Jang,   et al.

Title: Surface mount type crystal oscillator
Patent Number: 7,522,006 Issued on 04/21/2009 to Mizumura,   et al.

Title: K.sub.FM frequency tracking system using an analog correlator
Patent Number: 7,522,005 Issued on 04/21/2009 to Groe,   et al.

Title: High-frequency electronic switch, and burst wave generating device using the same and short range radar using the same
Patent Number: 7,522,004 Issued on 04/21/2009 to Saito

Title: Constant margin CMOS biasing circuit
Patent Number: 7,522,003 Issued on 04/21/2009 to Seth,   et al.

Title: Biasing current to speed up current mirror settling time
Patent Number: 7,522,002 Issued on 04/21/2009 to Pelli,   et al.

Title: Power amplifier
Patent Number: 7,522,001 Issued on 04/21/2009 to Yamamoto,   et al.

Title: Design structure for a serial link output stage differential amplifier
Patent Number: 7,522,000 Issued on 04/21/2009 to Cox,   et al.

Title: Differential amplifier and sampling and holding circuit
Patent Number: 7,521,999 Issued on 04/21/2009 to Kurose,   et al.

Title: Operational amplifier and scanning electron microscope using the same
Patent Number: 7,521,998 Issued on 04/21/2009 to Okayama

Title: Low-power variable gain amplifier
Patent Number: 7,521,997 Issued on 04/21/2009 to Beck,   et al.

Title: Differential amplifier and radio system with a differential amplifier
Patent Number: 7,521,996 Issued on 04/21/2009 to Kluge

Title: Inverted doherty amplifier with increased off-state impedence
Patent Number: 7,521,995 Issued on 04/21/2009 to Krvavac

Title: Three-stage amplifier
Patent Number: 7,521,994 Issued on 04/21/2009 to Theus,   et al.

Title: Substrate stress signal amplifier
Patent Number: 7,521,993 Issued on 04/21/2009 to O'Neill,   et al.

Title: Current-integrating amplifier
Patent Number: 7,521,992 Issued on 04/21/2009 to Hagleitner,   et al.

Title: Balanced band-pass filter for radio receivers
Patent Number: 7,521,991 Issued on 04/21/2009 to Barak,   et al.

Title: Noise reduction circuits
Patent Number: 7,521,990 Issued on 04/21/2009 to Bybee

Title: Distribution of an electric quantity through a circuit
Patent Number: 7,521,989 Issued on 04/21/2009 to Vimercati,   et al.

Title: Voltage booster for semiconductor device and semiconductor memory device using same
Patent Number: 7,521,988 Issued on 04/21/2009 to Shin

Title: Multiple supply voltage select circuit for reduced supply voltage levels
Patent Number: 7,521,987 Issued on 04/21/2009 to Cullen,   et al.

Title: Switch element driver circuit and semiconductor device
Patent Number: 7,521,986 Issued on 04/21/2009 to Mitsuda

Title: Method for regulating temperature and circuit therefor
Patent Number: 7,521,985 Issued on 04/21/2009 to Ball,   et al.

Title: Driving configuration of a switch
Patent Number: 7,521,984 Issued on 04/21/2009 to Ricotti

Title: High-voltage switch with low output ripple for non-volatile floating-gate memories
Patent Number: 7,521,983 Issued on 04/21/2009 to Ragone,   et al.

Title: Drive circuit for driving power device
Patent Number: 7,521,982 Issued on 04/21/2009 to Shimizu

Title: Mixer with carrier leakage calibration
Patent Number: 7,521,981 Issued on 04/21/2009 to Ng,   et al.

Title: Process and temperature-independent voltage controlled attenuator and method
Patent Number: 7,521,980 Issued on 04/21/2009 to Koen

Title: Ternary pulse generation circuit
Patent Number: 7,521,979 Issued on 04/21/2009 to Tanimoto

Title: Clock driver
Patent Number: 7,521,978 Issued on 04/21/2009 to Kim,   et al.

Title: Voltage-controlled oscillator generating output signal finely tunable in wide frequency range and variable delay circuits included therein
Patent Number: 7,521,977 Issued on 04/21/2009 to Ko

Title: Low power high speed latch for a prescaler divider
Patent Number: 7,521,976 Issued on 04/21/2009 to Sudjian,   et al.

Title: Output buffer with slew rate control utilizing an inverse process dependent current reference
Patent Number: 7,521,975 Issued on 04/21/2009 to Biesterfeldt,   et al.

Title: Translational phase locked loop using a quantized interpolated edge timed synthesizer
Patent Number: 7,521,974 Issued on 04/21/2009 to Kirschenmann

Title: Clock-skew tuning apparatus and method
Patent Number: 7,521,973 Issued on 04/21/2009 to Anemikos,   et al.

Title: Fifty percent duty cycle clock divider circuit and method
Patent Number: 7,521,972 Issued on 04/21/2009 to Wilson,   et al.

Title: Buffer circuit
Patent Number: 7,521,971 Issued on 04/21/2009 to Yamazaki

Title: High voltage tolerant input buffer
Patent Number: 7,521,970 Issued on 04/21/2009 to Gupta,   et al.

Title: Switch sequencing circuit systems and methods
Patent Number: 7,521,969 Issued on 04/21/2009 to Booth,   et al.

Title: Slew rate control for driver circuit
Patent Number: 7,521,968 Issued on 04/21/2009 to Dreps,   et al.

Title: Methods of reducing data dependent noise
Patent Number: 7,521,967 Issued on 04/21/2009 to Kwon,   et al.

Title: USB 2.0 transmitter using only 2.5 volt CMOS devices
Patent Number: 7,521,966 Issued on 04/21/2009 to Chong,   et al.

Title: 5 volt tolerant IO scheme using low-voltage devices
Patent Number: 7,521,965 Issued on 04/21/2009 to Oertle,   et al.

Title: High-speed level-shifting circuit
Patent Number: 7,521,964 Issued on 04/21/2009 to Luo,   et al.

Title: System and method for providing a low standby power interface for a low voltage I2C compatible bus
Patent Number: 7,521,963 Issued on 04/21/2009 to Xin-LeBlanc

Title: Semiconductor integrated circuit apparatus
Patent Number: 7,521,962 Issued on 04/21/2009 to Kondou

Title: Method and system for partially reconfigurable switch
Patent Number: 7,521,961 Issued on 04/21/2009 to Anderson

Title: Integrated circuit including programmable logic and external-device chip-enable override control
Patent Number: 7,521,960 Issued on 04/21/2009 to Balasubramanian,   et al.

Title: Configurable IC having a routing fabric with storage elements
Patent Number: 7,521,959 Issued on 04/21/2009 to Teig

Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof Number:7,384,775 from the United States Patent and Trademark Office (PTO) owispatent

Home    Author Login    Submit Article    Article Search    Add Your Link    Edit Your Link    Contact Us    Advertising    Disclaimer

   

 
Web LinkGrinder.com

Top Breaking News
     Ghana Combating Counterfeit Drugs by Scott Stearns
     UNICEF Concerned About Displaced Children in Northwest Pakistan by Lisa Schlein
     Report Says Public Corruption a Continuing Problem for East Africa by Alan Boswell

Title: Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof

Abstract: The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode polypeptides that are surface localized on Streptococcus pneumoniae. Thus, the invention relates to Streptococcus pneumoniae open reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by the Streptococcus pneumoniae open reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Streptococcus pneumoniae infection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with Streptococcus pneumoniae. In particular embodiments, the immunogenic compositions are used for the treatment or prevention of systemic diseases which are induced or exacerbated by Streptococcus pneumoniae. In other embodiments, the immunogenic compositions are used for the treatment or prevention of non-systemic diseases, particularly of the otitis media, which are induced or exacerbated by Streptococcus pneumoniae.

Patent Number: 7,384,775 Issued on 06/10/2008 to Zagursky,   et al.


Inventors: Zagursky; Robert John (Victor, NY), Masi; Amy Wadhams (Caledonia, NY), Green; Bruce Arthur (New City, NY), Chakravarti; Deb Narayan (Claremont, CA), Russell; David Parrish (Canandaigua, NY), Wooters; Joseph Lawrence (Brighton, MA)
Assignee: Wyeth (Madison, NJ)
Appl. No.: 10/474,776
Filed: April 12, 2002
PCT Filed: April 12, 2002
PCT No.: PCT/US02/11524
371(c)(1),(2),(4) Date: January 05, 2004
PCT Pub. No.: WO02/083855
PCT Pub. Date: October 24, 2002


Related U.S. Patent Documents

Application NumberFiling DatePatent NumberIssue Date
60283948Apr., 2001
60284443Apr., 2001

Current U.S. Class: 435/252.3 ; 424/234.1; 424/244.1; 435/320.1; 435/325; 435/69.1; 435/69.3; 536/23.7; 536/24.32
Field of Search: 435/69.1,252.3,320.1,325,69.3 536/23.7,24.32 424/244.1,234.1


References Cited [Referenced By]

U.S. Patent Documents
6420135 July 2002 Kunsch et al.
6573082 June 2003 Choi et al.
6800744 October 2004 Doucette-Stamm et al.
6887663 May 2005 Choi et al.
2001/0053519 December 2001 Fodor et al.
Foreign Patent Documents
WO 98/18931 May., 1998 WO
WO 98/23631 Jun., 1998 WO
WO 00/15769 Mar., 2000 WO
WO 00/17644 Mar., 2000 WO
WO 00/58475 Oct., 2000 WO
WO 00/65026 Nov., 2000 WO
WO 01/14421 Mar., 2001 WO
WO 01/40472 Jun., 2001 WO
WO 01/81380 Nov., 2001 WO
WO 02/053761 Jul., 2002 WO
WO 02/077021 Oct., 2002 WO
WO 02/079241 Oct., 2002 WO
WO 077021 Oct., 2002 WO
WO 03/054007 Jul., 2003 WO

Other References

Clinical and Diagnostic Laboratory Immunology, Jan. 2005, pp. 19-27, vol. 12, No. 1. cited by examiner .
Int Microbiol. Sep. 2004; 7(3): 163-71. cited by examiner .
Infect Immun. Dec. 1994;62(12):5384-96. cited by examiner .
Mol. Microbiol. 1991, 5(7): 1755 67. cited by examiner .
Molecular and Cellular Biology, 8(3): 1247 1252, 1988. cited by examiner .
The Journal of Cell Biology, 111:2129 2138, 1990. cited by examiner .
"Peptide Hormones", edited by Parsons, J.A., University Park Press, Jun. 1976, pp. 1-7. cited by examiner .
Journal of Molecular Biology, vol. 244, pp. 332 350 (1994). cited by examiner .
Journal of Leukocyte Biology, vol. 61, No. 5, pp. 545 550 (1997. cited by examiner .
BioEssays, vol. 18, No. 12, pp. 973 981,1996. cited by examiner .
Gerhold et al. [BioEssays, vol. 18, No. 12, pp. 973-981(1996)]; Wells et al. [Journal of Leukocyte Biology, vol. 61, No. 5, pp. 545-550 (1997)]; Russell et al. [Journal of Molecular Biology, vol. 244, pp. 332-350 (1994)]. cited by examiner .
Rudinger et al, in "Peptide Hormones", edited by Parsons, J.A., University Park Press, Jun. 1976. cited by examiner .
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990. cited by examiner .
Lazar et al., Molecular and Cellular Biology, 8(3): 1247-1252, 1988. cited by examiner .
Jobling et al. (Mol. Microbiol. 1991, 5(7): 1755-67. cited by examiner .
Geneseq [Online] Oct. 23, 1998, "Streptococcus pneumoniae genome fragment SEQ ID No. 214." retrieved from EBI accession No. GSN: AAV52347, Data base accession No. AAV52347 (the whole document). cited by other .
Zhou Lixin et al., "Characterization of IS1167, a new insertion sequence in Streptococcus pneumoniae" Plasmid, vol. 33, No. 2, 1995, pp. 127-138, XP002278433, ISSN: 0147-619X. cited by other .
Lange, R. et al., "Domain organization and molecular characterization of 13 two-component systems identified by genome sequencing of Streptococcus pneumoniae" Gene, Elsevier, Amsterdam, NL, vol. 237, No. 1, Sep. 3, 1999, pp. 223-234. XP004183515. cited by other .
Wizemann, T. M. et al., "Use of a whole genome approach to identify vacine molecules affording protection against Streptococcus pneumoniae infection" Infection and Immunity, American Society for Microbiology, Washington, U.S., vol. 69, No. 3, Mar. 2001, pp. 1593-1598, XP002263818, ISSN: 0019-9567. cited by other .
Adamou J. et al., "Identification and Characterizaion of a Novel Family in Pneumococcal Proteins That are Protective against Sepsis." Infection and Immunity, American Society for Microbiology, Washington, U.S., vol. 69, No. 2, Feb. 2001, pp. 949-958, XP002282664, ISSN: 0019-9567. cited by other .
Fischer-Romero Carmen et al., "Development and evaluation of a broad-range PCR-ELISA assay with Borrelia burgdorferi and Streptococcus pneumoniae as model organisms for reactive arthritis and bacterial meningitis" Journal of Microbiological Methods, vol. 40, No. 1, Mar. 200, pp. 79-88. XP002396765. cited by other .
Rimini, Rebecaa et al., "Global analysis of transcription kinetics during competence development in Streptococcus pneumoniae using high-density DNA arrays" Molecular Microbiology, vol. 36, No. 6, Jun. 2000, pp. 1279-1292. XP002396766. cited by other .
Tettelin H. et al., "Complete genome sequence of a virulent isolate of Streptococcus pneumoniae" Science, American Association For the Advancement of Science, US, vol. 293, No. 5529, Jul. 20, 2001, pp. 498-506. XP002263816. cited by other .
Hoskins, J. et al., "Genome of the Bacterium Streptcoccus pneumoniae Strain R6" Journal of Bacteriology, Washington, DC, US, vol. 183, No. 19, Oct. 2001, pp. 5709-5717. XP002231307. cited by other .
Geneseq [Online] Oct. 3, 2002, "Streptococcus pneumoniae type 4 strain coding region #1060 Seq ID No. 2119." retrieved from EBI accession No. GSN: ABX06943, Database accession No. ABX06943 (the whole document). cited by other .
Genseq [Online] Oct. 3, 2002, "Streptococcus pneumoniae type 4 strain coding region #1231 Seq ID No. 2461." retrieved from EBI accession No. GSN: ABX06943, Database accession No. GSN: ABX06943. cited by other .
Geneseq [Online] Oct. 3, 2002, "Streptococcus pneumoniae type 4 strain coding region #1744 Seq ID No. 3487." retrieved from EBI accession No. GSN: ABX07456, Database accession No. ABX07456. cited by other .
Geneseq [Online] Oct. 3, 2002, "Streptococcus pneumoniae type 4 strain coding region #1060 Seq ID No. 2120." retrieved from EBI accession No. GSP: ABU01484, Database accession No. ABU01484. cited by other .
Geneseq [Online] Oct. 3, 2002, "Streptococcus pneumoniae type 4 strain coding region #1231 Seq ID No. 2462." retrieved from EBI accession No. GSP: ABU01484, Database accession No. ABU01484. cited by other .
Geneseq [Online] Oct. 3, 2002, "Streptococcus pneumoniae type 4 strain coding region #1744 Seq ID No. 3488." retrieved from EBI accession No. GSP: ABU02167, Database accession No. ABU02167. cited by other.

Primary Examiner: Foley; Shanon
Assistant Examiner: Baskar; Padma
Attorney, Agent or Firm: Ronning, Jr.; Royal N.

Parent Case Text



This application claims priority from provisional application Ser. No. 60/283,948, filed on Apr. 16, 2001, the entire disclosure of which is hereby incorporated by reference and provisional application Ser. No. 60/284,443, filed Apr. 18, 2001, the entire disclosure of which is hereby incorporated by reference.
Claims



What is claimed is:

1. An isolated Streptococcus pneumoniae polynucleotide comprising at least 95% identity to the full length nucleotide sequence of SEQ ID NO:91, and wherein the polynucleotide encodes an immunogenic polypeptide.

2. An isolated polynucleotide, wherein the polynucleotide is a complement to the nucleotide sequence of SEQ ID NO:91.

3. The polynucleotide of claim 1 wherein the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA and RNA.

4. The polynucleotide of claim 1 wherein the polynucleotide further comprises heterologous nucleotides.

5. An isolated polynucleotide which hybridizes to the full length nucleotide sequence of SEQ ID NO:91, or a complement thereof, under high stringency hybridization conditions, wherein the high stringency hybridization is at 65.degree. C. with lxSSC followed by a 65.degree. C. wash with O.3.times.SSC, and wherein the polynucleotide encodes an immunogenic polypeptide.

6. An isolated Streptococcus pneumoniae polynucleotide, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:91, and encodes a polypeptide, selected from the group consisting of: (a) a Streptococcus pneumoniae polypeptide having 0, 1 or 2 transmembrane domains; (b) a Streptococcus pneumoniae polypeptide having 3 or more transmembrane domains; (c) a Streptococcus pneumoniae polypeptide having an outer membrane domain or a periplasmic domain; (d) a Streptococcus pneumoniae polypeptide having an inner membrane domain; (e) a Streptococcus pneumoniae polypeptide identified by Blastp analysis; (f) a Streptococcus pneumoniae polypeptide identified by Pfam analysis; (g) a Streptococcus pneumoniae lipoprotein; (h) a Streptococcus pneumoniae polypeptide having a LPXTG motif, wherein the polypeptide is covalently attached to the peptidoglycan layer; (i) a Streptococcus pneumoniae polypeptide having a peptidoglycan binding motif, wherein the polypeptide is associated with the peptidoglycan layer; (j) a Streptococcus pneumoniae polypeptide having a signal sequence and a C-terminal Tyrosine or a C-terminal Phenylalanine amino acid; (k) a Streptococcus pneumoniae polypeptide having a tripeptide RGD amino acid sequence; (l) a Streptococcus pneumoniae polypeptide identified by proteomics as surface exposed; and (m) a Streptococcus pneumoniae polypeptide identified by proteomics as membrane associated.

7. The polynucleotide of claim 6, wherein the polynucleotide is a complement to the nucleotide sequence of SEQ ID NO:91.

8. The polynucleotide of claim 7, wherein the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA and RNA.

9. The polynucleotide of claim 8, wherein the polynucleotide further comprises heterologous nucleotides.

10. The polynucleotide of claim 9, wherein the polynucleotide encodes a fusion polypeptide.

11. The polynucleotide of claim 6, wherein the polynucleotide of SEQ ID NO:91 encodes a polypeptide having 0, 1 or 2 transmembrane domains.

12. The polynucleotide of claim 6, wherein the polynucleotide of SEQ ID NO:91 encodes a polypeptide having an inner membrane domain.

13. The polynucleotide of claim 6, wherein the polynucleotide of SEQ ID NO:91 encodes a polypeptide identified by proteomics as surface exposed.

14. An isolated recombinant expression vector comprising a polynucleotide having at least 95% identity to the full length nucleotide sequence of SEQ ID NO:91, wherein the polynucleotide encodes for an immunogenic polypeptide.

15. The vector of claim 14, wherein the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA, RNA and antisense RNA.

16. The vector of claim 15, wherein the polynucleotide further comprises heterologous nucleotide sequences.

17. The vector of claim 16, wherein the polynucleotide is operatively linked to one or more gene expression regulatory elements.

18. The vector of claim 17, wherein the polynucleotide encodes a polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:306.

19. The vector of claim 14, wherein the vector is a plasmid.

20. An isolated genetically engineered host cell, transfected, transformed or infected with the vector of claim 14.

21. The host cell of claim 20, wherein the host cell is a bacterial cell.

22. The host cell of claim 21, wherein the polynucleotide is expressed to produce the encoded polypeptide.

23. An isolated polynucleotide of a Streptococcus pneumoniae, wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:306.

24. An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO: 91.

25. An isolated polynucleotide that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 306.

26. An isolated polynucleotide that encodes a polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 306, wherein the polypeptide is an immunogenic polypeptide.

27. A method for producing a polypeptide which comprises culturing the genetically engineered host cell of claim 21 under conditions suitable to produce the polypeptide and recovering the polypeptide from the culture.

28. A kit comprising a container containing an isolated polynucleotide of claim 1.

29. The kit of claim 28, wherein the polynucleotide is a primer or a probe.

30. The kit of claim 29, wherein the polynucleotide is a primer and the kit further comprises a container containing a polymerase.

31. The kit of claim 28, wherein the kit further comprises a container containing dNTP.

32. An immunogenic composition comprising a polynucleotide having a nucleotide sequence of SEQ ID NO:91 and is comprised in an expression vector.

33. The immunogenic composition of claim 32, wherein the vector is plasmid DNA.

34. The immunogenic composition of claim 33, wherein the polynucleotide further comprises heterologous nucleotides.

35. The immunogenic composition of claim 34, wherein the polynucleotide is operatively linked to one or more gene expression regulatory elements.

36. The immunogenic composition of claim 35, wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:306.

37. The immunogenic composition of claim 36, further comprising one or more adjuvants.
Description



FIELD OF THE INVENTION

The invention relates to Streptococcus pneumoniae genomic sequence and polynucleotide sequences encoding polypeptides of Streptococcus pneumoniae. More particularly, the invention relates to newly identified polynucleotide open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode Streptococcus pneumoniae polypeptides, preferably polypeptides that are surface localized, secreted, membrane associated or exposed on Streptococcus pneumoniae.

BACKGROUND OF THE INVENTION

Streptococcus pneumoniae infections are a major cause of human diseases such as otitis media, bacteremia, meningitis, septic arthritis and fatal pneumonia worldwide (Butler et al, 1999; James and Thomas, 2000). Over the past 10-20 years, Streptococcus pneumoniae has developed resistance to most antibiotics used for its treatment. In fact, it is common for Streptococcus pneumoniae to become resistant to more than one class of antibiotic, e.g., .beta.-lactams, macrolides, lincosamides, trimethoprim-sulfamethoxazole, tetracyclines (Tauber, 2000), meaning Streptococcus pneumoniae treatment is becoming more difficult.

Thus, the rapid emergence of multi-drug resistant pneumococcal strains throughout the world has led to increased emphasis on prevention of pneumococcal infections by immunization (Goldstein and Garau, 1997). The currently available 23-valent pneumococcal capsular polysaccharide vaccine, is not effective in children of less than 2 years of age or in immunocompromised patients, two of the major populations at risk from pneumococcal infection (Douglas et al., 1983). A 7-valent pneumococcal polysaccharide-protein conjugate vaccine, recently licensed in the United States, was shown to be highly effective in infants and children against systemic pneumococcal disease caused by the vaccine serotypes and against cross-reactive capsular serotypes (Shinefield and Black, 2000). The seven capsular types cover greater than 80% of the invasive disease isolates in children in the United States, but only 57-60% of disease isolates in other areas of the world (Hausdorff et al, 2000). There is therefore an immediate need for a cost-effective vaccine to cover most or all of the disease causing serotypes of pneumococci. While this can be achieved by adding conjugates covering additional serotypes, efforts continue to find non-capsular vaccine antigens that are conserved among all pneumococcal serotypes and effective against pneumococcal disease.

Protein antigens of Streptococcus pneumoniae have been evaluated for protective efficacy in animal models of pneumococcal infection. Some of the most commonly studied candidate antigens include the PspA proteins, PsaA lipoprotein, and the CbpA protein. Numerous studies have shown that PspA protein is a virulence factor (Crain et al., 1990; McDaniel et al., 1984) but it is antigenically variable among pneumococcal strains. A recent study has indicated that some antigenically conserved regions of a recombinant PspA variant may elicit cross-reactive antibodies in human adults (Nabors et al., 2000). PsaA, a 37 kD lipoprotein with similarity to other gram-positive adhesins, is involved in Mn.sup.+ transport in pneumococci (Sampson et al., 1994; Dintilhac et al., 1997) and has also been shown to be protective in mouse models of systemic disease (Talkington et al., 1996). The surface exposed choline binding protein CbpA is antigenically conserved and protective in mouse models of pneumococcal disease (Rosenow et al., 1997). Since nasopharyngeal colonization is a prerequisite for otic disease, intranasal immunization of mice with pneumococcal proteins and appropriate mucosal adjuvants has been used to enhance the mucosal antibody response and thus, the effectiveness of candidate antigens (Yamamoto et al., 1998; Briles et al., 2000).

While the PspA protein, PsaA lipoprotein and the CbpA protein antigens appear promising, it is possible that no one protein antigen will be effective against all Streptococcus pneumoniae serotypes. Laboratories therefore continue to search for additional candidates that are antigenically conserved and elicit antibodies that reduce colonization (important for otitis media), are protective against systemic disease, or both. Thus, there is an immediate need for a cost-effective vaccine to cover most or all of the disease causing serotypes of Streptococcus pneumoniae and methods of diagnosing Streptococcus pneumoniae infection. A better understanding of the genetic and molecular levels of Streptococcus pneumoniae infection will provide the basis for further development of preventative treatments, therapeutic treatments, new diagnostics and vaccine strategies which are specific for Streptococcus pneumoniae.

SUMMARY OF THE INVENTION

The present invention broadly relates to Streptococcus pneumoniae genomic sequence. More particularly, the invention relates to newly identified polynucleotide open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode polypeptides that are surface localized, membrane associated, secreted, or exposed on Streptococcus pneumoniae.

Thus, in certain aspects, the invention relates to Streptococcus pneumoniae open reading frames that encode Streptococcus pneumoniae polypeptides. In preferred embodiments, these Streptococcus pneumoniae polypeptides are antigenic polypeptides. As defined hereinafter, a Streptococcus pneumoniae antigenic polypeptide, antigen or immunogen, is a Streptococcus pneumoniae polypeptide that is immunoreactive with an antibody or is a Streptococcus pneumoniae polypeptide that elicits an immune response. In other embodiments, the invention relates to the polynucleotides encoding these antigenic polypeptides. In other aspects, the invention relates to vectors comprising open reading frame sequences and cells or animals transformed, transfected or infected with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Streptococcus pneumoniae infection. The invention further relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with Streptococcus pneumoniae. In a preferred embodiment, the immunogenic compositions are used for the treatment or prevention of systemic diseases that are induced or worsened by Streptococcus pneumoniae. In another preferred embodiment, the immunogenic compositions are used for the treatment or prevention of non-systemic diseases, particularly of the otitis media, which are induced or worsened by Streptococcus pneumoniae.

In particular embodiments, an isolated polynucleotide of the present invention is a polynucleotide comprising a nucleotide sequence having at least about 95% identity to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO:431 through SEQ ID NO:591, a degenerate variant thereof, or a fragment thereof. As defined hereinafter, a "degenerate variant" is defined as a polynucleotide that differs from the nucleotide sequence shown in SEQ ID NO:1 through SEQ ID NO:215 and SEQ ID NO:431 through SEQ ID NO:591 (and fragments thereof due to degeneracy of the genetic code, but still encodes the same Streptococcus pneumoniae polypeptide (i.e., SEQ ID NO:216 through SEQ ID NO:430 and SEQ ID NO:592 through SEQ ID NO:752) as that encoded by the nucleotide sequence shown in SEQ ID NO:1 through SEQ ID NO:215 and SEQ ID NO:431 through SEQ ID NO:591.

In other embodiments, the polynucleotide is a complement to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO:431 through SEQ ID NO:591, a degenerate variant thereof, or a fragment thereof. In yet other embodiments, the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA and RNA and may further comprise heterologous nucleotides.

In another embodiment, the invention comprises an isolated polynucleotide that hybridizes to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO:431 through SEQ ID NO:591, a complement thereof, a degenerate variant thereof, or a fragment thereof, under high stringency hybridization conditions. In yet other embodiments, the polynucleotide hybridizes under intermediate stringency hybridization conditions.

In a preferred embodiment, an isolated polynucleotide of a Streptococcus pneumoniae genomic sequence comprises a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO:431 through SEQ ID NO:591, a fragment thereof, or a degenerate variant thereof, and encodes a polypeptide, a biological equivalent thereof, or a fragment thereof, selected from the group consisting of a Streptococcus pneumoniae polypeptide having 0, 1 or 2 transmembrane domains, a Streptococcus pneumoniae polypeptide having 3 or more transmembrane domains, a Streptococcus pneumoniae polypeptide having an outer membrane domain or a periplasmic domain, a Streptococcus pneumoniae polypeptide having an inner membrane domain, a Streptococcus pneumoniae polypeptide identified by Blastp analysis, a Streptococcus pneumoniae polypeptide identified by Pfam analysis, a Streptococcus pneumoniae lipoprotein, a Streptococcus pneumoniae polypeptide having a LPXTG motif, wherein the polypeptide is covalently attached to the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a peptidoglycan binding motif, wherein the polypeptide is associated with the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a signal sequence and a C-terminal Tyrosine or Phenylalanine amino acid, a Streptococcus pneumoniae polypeptide having a tripeptide RGD sequence, a Streptococcus pneumoniae polypeptide identified by proteomics as surface exposed and a Streptococcus pneumoniae polypeptide identified by proteomics as membrane associated.

In other embodiments, the isolated polynucleotide is a complement to a Streptococcus pneumoniae genomic sequence comprising a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO:431 through SEQ ID NO:591, a fragment thereof, or a degenerate variant thereof, and encodes a polypeptide, a biological equivalent thereof, or a fragment thereof, selected from the group consisting of a Streptococcus pneumoniae polypeptide having 0, 1 or 2 transmembrane domains, a Streptococcus pneumoniae polypeptide having 3 or more transmembrane domains, a Streptococcus pneumoniae polypeptide having an outer membrane domain or a periplasmic domain, a Streptococcus pneumoniae polypeptide having an inner membrane domain, a Streptococcus pneumoniae polypeptide identified by Blastp analysis, a Streptococcus pneumoniae polypeptide identified by Pfam analysis, a Streptococcus pneumoniae lipoprotein, a Streptococcus pneumoniae polypeptide having a LPXTG motif, wherein the polypeptide is covalently attached to the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a peptidoglycan binding motif, wherein the polypeptide is associated with the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a signal sequence and a C-terminal Tyrosine or Phenylalanine amino acid, a Streptococcus pneumoniae polypeptide having a tripeptide RGD sequence, a Streptococcus pneumoniae polypeptide identified by proteomics as surface exposed and a Streptococcus pneumoniae polypeptide identified by proteomics as membrane associated. In certain embodiments, the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA and RNA and may further comprise heterologous nucleotides. In still other embodiments, the polynucleotide encodes a fusion polypeptide.

In a preferred embodiment, a polynucleotide encoding a polypeptide having 0, 1 or 2 transmembrane domains comprises a nucleotide sequence chosen from one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 116, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 165, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 179, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 192, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 207, SEQ ID NO: 209 and SEQ ID NO: 210.

In another preferred embodiment, a polynucleotide encoding a polypeptide having 3 or more transmembrane domains comprises a nucleotide sequence chosen from one of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 59, SEQ ID NO: 65, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 124, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 198, SEQ ID NO: 203, SEQ ID NO: 206, SEQ ID NO: 208, SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214 and SEQ ID NO: 215.

In other preferred embodiments, a polynucleotide encoding a polypeptide having an outer membrane domain or a periplasmic domain comprises a nucleotide sequence chosen from one of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 23, SEQ ID NO: 39, SEQ ID NO: 50, SEQ ID NO: 62, SEQ ID NO: 67, SEQ ID NO: 78, SEQ ID NO: 85, SEQ ID NO: 125, SEQ ID NO: 134, SEQ ID NO: 147, SEQ ID NO: 165, SEQ ID NO: 172 and SEQ ID NO: 179.

In other preferred embodiments, a polynucleotide encoding a polypeptide having an inner membrane domain comprises a nucleotide sequence chosen from one of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 65, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86 SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 203, SEQ ID NO: 206, SEQ ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214 and SEQ ID NO: 215.

In yet another preferred embodiment, a polynucleotide encoding a polypeptide identified by Blastp analysis comprises a nucleotide sequence chosen from one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, SEQ ID NO: 213 and SEQ ID NO: 214.

In still further preferred embodiments, a polynucleotide encoding a polypeptide identified by Pfam analysis comprises a nucleotide sequence chosen from one of SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 89, SEQ ID NO: 92, SEQ ID NO: 104, SEQ ID NO: 111, SEQ ID NO: 116, SEQ ID NO: 119, SEQ ID NO: 128, SEQ ID NO: 137, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 180, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO 189, SEQ ID NO: 195, SEQ ID NO: 198, SEQ ID NO 199, SEQ ID NO: 205, SEQ ID NO: 212 and SEQ ID NO: 213.

In another preferred embodiment, a polynucleotide encoding a lipoprotein comprises a nucleotide sequence chosen from one of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 21, SEQ ID NO: 26, SEQ ID NO: 34, SEQ ID NO: 62, SEQ ID NO: 67, SEQ ID NO: 85, SEQ ID NO: 134, SEQ ID NO: 147, SEQ ID NO: 150, SEQ ID NO: 168, SEQ ID NO: 170 and SEQ ID NO: 173.

In other preferred embodiments, a polynucleotide encoding a polypeptide having a LPXTG motif and is covalently attached to the peptidoglycan layer comprises a nucleotide sequence chosen from one of SEQ ID NO: 13, SEQ ID NO: 21, SEQ ID NO: 34 and SEQ ID NO: 170; or a polynucleotide encoding a polypeptide having a peptidoglycan binding motif and associated with the peptidoglycan layer comprises a nucleotide sequence chosen from one of SEQ ID NO: 25, SEQ ID NO: 49 and SEQ ID NO: 110.

In another preferred embodiment, a polynucleotide encoding a polypeptide having a signal sequence and a C-terminal Tyrosine or Phenylalanine amino acid comprises a nucleotide sequence chosen from one of SEQ ID NO:11, SEQ ID NO:39, SEQ ID NO:73, SEQ ID NO:97, SEQ ID NO:106, SEQ ID NO: 125 and SEQ ID NO:187.

In yet another preferred embodiment, a polynucleotide encoding a polypeptide having a tripeptide RGD sequence that potentially is involved in cell attachment comprises a nucleotide sequence chosen from one of SEQ ID NO:1, SEQ ID NO:21, SEQ ID NO:66 and SEQ ID NO:67.

In another preferred embodiment, a polynucleotide encoding a polypeptide identified by proteomics as surface exposed comprises a nucleotide sequence chosen from one of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:46, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:91, SEQ ID NO:103, SEQ ID NO:116, SEQ ID NO:128, SEQ ID NO:131, SEQ ID NO:136, SEQ ID NO:151, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:164, SEQ ID NO:172, SEQ ID NO:176, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:182 and SEQ ID NO:205.

In still another embodiment, a polynucleotide encoding a polypeptide identified by proteomics as membrane associated comprises a nucleotide sequence chosen from one of SEQ ID NO:431 through SEQ ID NO:591.

In certain aspects, the invention relates to Streptococcus pneumoniae polypeptides. More particularly, the invention relates to Streptococcus pneumoniae polypeptides, more preferably antigenic polypeptides, encoded by Streptococcus pneumoniae polynucleotide open reading frames. Thus, in certain embodiments, an isolated polypeptide is encoded by a polynucleotide comprising a nucleotide sequence having at least about 95% identity to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO: 431 through SEQ ID NO: 591, a degenerate variant thereof, or a fragment thereof. In a preferred embodiment, the isolated polypeptide encoded by one of the above polynucleotides comprises an amino acid sequence having at least about 95% identity to an amino acid sequence chosen from one of SEQ ID NO: 216 through SEQ ID NO: 430 or SEQ ID NO: 592 through SEQ ID NO: 752, a biological equivalent thereof, or a fragment thereof. In other embodiments, the polypeptide is a fusion polypeptide. In a preferred embodiment, the polypeptide immunoreacts with seropositive serum of an individual infected with Streptococcus pneumoniae.

In preferred embodiments, the isolated polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least about 95% identity to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO: 431 through SEQ ID NO: 591, a degenerate variant thereof, or a fragment thereof, is further defined as a Streptococcus pneumoniae polypeptide having 0, 1 or 2 transmembrane domains, a Streptococcus pneumoniae polypeptide having 3 or more transmembrane domains, a Streptococcus pneumoniae polypeptide having an outer membrane domain or a periplasmic domain, a Streptococcus pneumoniae polypeptide having an inner membrane domain, a Streptococcus pneumoniae polypeptide identified by Blastp analysis, a Streptococcus pneumoniae polypeptide identified by Pfam analysis, a Streptococcus pneumoniae lipoprotein, a Streptococcus pneumoniae polypeptide having a LPXTG motif, wherein the polypeptide is covalently attached to the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a peptidoglycan binding motif, wherein the polypeptide is associated with the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a signal sequence and a C-terminal Tyrosine or Phenylalanine amino acid, a Streptococcus pneumoniae polypeptide having a tripeptide RGD sequence, a Streptococcus pneumoniae polypeptide identified by proteomics as surface exposed or a Streptococcus pneumoniae polypeptide identified by proteomics as membrane associated, where each of these groups has the set of ORFs identified above as within SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO: 431 through SEQ ID NO: 591.

In a particularly preferred embodiment, an isolated polypeptide comprises an amino acid sequence having at least about 95% identity to an amino acid sequence chosen from one of SEQ ID NO: 216 through SEQ ID NO: 430 or SEQ ID NO: 592 through SEQ ID NO: 752, a biological equivalent thereof, or a fragment thereof. In another embodiment, the polypeptide is a fusion polypeptide. In a particularly preferred embodiment, the polypeptide immunoreacts with seropositive serum of an individual infected with Streptococcus pneumoniae. In yet other preferred embodiments, the polypeptide is further defined as a Streptococcus pneumoniae polypeptide having 0, 1 or 2 transmembrane domains, a Streptococcus pneumoniae polypeptide having 3 or more transmembrane domains, a Streptococcus pneumoniae polypeptide having an outer membrane domain or a periplasmic domain, a Streptococcus pneumoniae polypeptide having an inner membrane domain, a Streptococcus pneumoniae polypeptide identified by Blastp analysis, a Streptococcus pneumoniae polypeptide identified by Pfam analysis, a Streptococcus pneumoniae lipoprotein, a Streptococcus pneumoniae polypeptide having a LPXTG motif, wherein the polypeptide is covalently attached to the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a peptidoglycan binding motif, wherein the polypeptide is associated with the peptidoglycan layer, a Streptococcus pneumoniae polypeptide having a signal sequence and a C-terminal Tyrosine or Phenylalanine amino acid, a Streptococcus pneumoniae polypeptide having a tripeptide RGD sequence, a Streptococcus pneumoniae polypeptide identified by proteomics as surface exposed or a Streptococcus pneumoniae polypeptide identified by proteomics as membrane associated.

In a preferred embodiment, a polypeptide having 0, 1 or 2 transmembrane domains comprises an amino acid sequence chosen from one of SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 260, SEQ ID NO: 262, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 270, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 296, SEQ ID NO: 298, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 304, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 315, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 328, SEQ ID NO: 331, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 349, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 380, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 394, SEQ ID NO: 398, SEQ ID NO: 400, SEQ ID NO: 402, SEQ ID NO: 407, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 422, SEQ ID NO: 424, SEQ ID NO: 425, a biological equivalent thereof, or a fragment thereof.

In another preferred embodiment, a polypeptide having 3 or more transmembrane domains comprises an amino acid sequence chosen from on of SEQ ID NO: 217, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 248, SEQ ID NO: 250, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 274, SEQ ID NO: 280, SEQ ID NO: 286, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 295, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 339, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 348, SEQ ID NO: 350, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 388, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 413, SEQ ID NO: 418, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, a biological equivalent thereof, or a fragment thereof.

In yet other preferred embodiments, a polypeptide having an outer membrane domain or a periplasmic domain comprises an amino acid sequence chosen from one of SEQ ID NO: 218, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 238, SEQ ID NO: 254, SEQ ID NO: 265, SEQ ID NO: 277, SEQ ID NO: 282, SEQ ID NO: 293, SEQ ID NO: 300, SEQ ID NO: 340, SEQ ID NO: 349, SEQ ID NO: 362, SEQ ID NO: 380, SEQ ID NO: 387, SEQ ID NO: 394, a biological equivalent thereof, or a fragment thereof.

In yet other preferred embodiments, a polynucleotide encoding a polypeptide having an inner membrane domain comprises an amino acid sequence chosen from one of SEQ ID NO: 217, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 280, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 288, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 301 SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 388, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 418, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, a biological equivalent thereof, or a fragment thereof.

In still another preferred embodiment, a polypeptide identified by Blastp analysis comprises an amino acid sequence chosen from one of SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 222, SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 231, SEQ ID NO: 235, SEQ ID NO: 239, SEQ ID NO: 242, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 263, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 280, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 313, SEQ ID NO: 315, SEQ ID NO: 318, SEQ ID NO: 320, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 342, SEQ ID NO: 344, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO: 356, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 372, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 384, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 406, SEQ ID NO: 408, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, a biological equivalent thereof, or a fragment thereof.

In other preferred embodiments, a polypeptide identified by Pfam analysis comprises an amino acid sequence chosen from one of SEQ ID NO: 219, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 255, SEQ ID NO: 260, SEQ ID NO: 270, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 304, SEQ ID NO: 307, SEQ ID NO: 319, SEQ ID NO: 326, SEQ ID NO: 331, SEQ ID NO: 334, SEQ ID NO: 343, SEQ ID NO: 352, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 364, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 384, SEQ ID NO: 386, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO 404, SEQ ID NO: 410, SEQ ID NO: 413, SEQ ID NO 414, SEQ ID NO: 420, SEQ ID NO: 427, SEQ ID NO: 428, a biological equivalent thereof, or a fragment thereof.

In one preferred embodiment, a polypeptide is a lipoprotein and comprises an amino acid sequence chosen from one of SEQ ID NO: 218, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 228, SEQ ID NO: 236, SEQ ID NO: 241, SEQ ID NO: 249, SEQ ID NO: 277, SEQ ID NO: 282, SEQ ID NO: 300, SEQ ID NO: 349, SEQ ID NO: 362, SEQ ID NO: 365, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 388, a biological equivalent thereof, or a fragment thereof.

In certain other preferred embodiments, a polypeptide having a LPXTG motif and covalently attached to the peptidoglycan layer, comprises an amino acid sequence chosen from one of SEQ ID NO: 228, SEQ ID NO: 236, SEQ ID NO: 249, SEQ, SEQ ID NO: 385, a biological equivalent thereof, or a fragment thereof; or a polypeptide having a peptidoglycan binding motif and associated with the peptidoglycan layer comprises an amino add sequence chosen from one of SEQ ID NO: 240, SEQ ID NO: 264, SEQ ID NO: 325, a biological equivalent thereof, or a fragment thereof.

In another preferred embodiment, a polypeptide having a signal sequence and a C-terminal Tyrosine or Phenylalanine amino acid comprises an amino acid sequence chosen from one of SEQ ID NO:226, SEQ ID NO:254, SEQ ID NO:289, SEQ ID NO:312, SEQ ID NO:321, SEQ ID NO: 340, SEQ ID NO:402, a biological equivalent thereof, or a fragment thereof.

In yet another preferred embodiment, a polypeptide having a tripeptide RGD sequence that potentially is involved in cell attachment comprises an amino acid sequence chosen from one of SEQ ID NO:216, SEQ ID NO:236, SEQ ID NO:281, SEQ ID NO:282, a biological equivalent thereof, or a fragment thereof.

In still another embodiment, a polypeptide identified by proteomics as surface exposed comprises an amino acid sequence chosen from one of SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 261, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 284, SEQ ID NO: 286, SEQ ID NO: 289, SEQ ID NO: 306, SEQ ID NO: 318, SEQ ID NO: 331, SEQ ID NO: 343, SEQ ID NO: 346, SEQ ID NO: 351, SEQ ID NO: 366, SEQ ID NO: 371, SEQ ID NO: 374, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 387, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 420, a biological equivalent thereof, or a fragment thereof.

In yet another embodiment, a polypeptide identified by proteomics as membrane associated comprises an amino acid sequence chosen from one of SEQ ID NO: 592 through SEQ ID NO: 752, a biological equivalent thereof, or a fragment thereof.

In another aspect of the invention, the polypeptides are expressed and purified in a recombinant expression system. Thus, in certain embodiments, the invention provides a recombinant expression vector comprising a nucleotide sequence having at least about 95% identity to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO: 431 through SEQ ID NO: 591, a degenerate variant thereof, or a fragment thereof. In certain other embodiments, the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA, RNA and antisense RNA. In another embodiment, the polynucleotide comprised within the vector further comprises heterologous nucleotide sequences. In other embodiments, the polynucleotide is operatively linked to one or more gene expression regulatory elements. In yet other embodiments, the polynucleotide encodes a polypeptide comprising an amino acid sequence having at least about 95% identity to an amino acid sequence chosen from one of SEQ ID NO: 216 through SEQ ID NO: 430 or SEQ ID NO: 592 through SEQ ID NO: 752, a biological equivalent thereof, or a fragment thereof. In a preferred embodiment, the vector is a plasmid.

In another aspect of the invention, there is provided a genetically engineered host cell, transfected, transformed or infected with a recombinant expression vector comprising a nucleotide sequence having at least about 95% identity to a nucleotide sequence chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO: 431 through SEQ ID NO: 591, a degenerate variant thereof, or a fragment thereof. In a preferred embodiment, the host cell is a bacterial cell. In a further embodiment, the polynucleotide is expressed under suitable conditions to produce the encoded polypeptide, a biological equivalent thereof, or a fragment thereof, which is then recovered.

In other embodiments, the present invention provides an antibody specific for a Streptococcus pneumoniae polynucleotide chosen from one of SEQ ID NO: 1 through SEQ ID NO: 215 or SEQ ID NO: 431 through SEQ ID NO: 591, a fragment thereof, a degenerate variant thereof, or an antibody specific for a Streptococcus pneumoniae polypeptide chosen from one of SEQ ID NO: 216 through SEQ ID NO: 430 or SEQ ID NO: 592 through SEQ ID NO: 752, a biological equivalent thereof, or a fragment thereof. In certain embodiments, the antibody is selected from the group consisting of monoclonal, polyclonal, chimeric, humanized and single chain. In a preferred embodiment, the antibody is monoclonal. In another preferred embodiment, the antibody is humanized.

The present invention further provides pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection. Thus, in one embodiment an immunogenic composition is provided comprising a polypeptide having an amino acid sequence chosen from one or more of SEQ ID NO: 216 through SEQ ID NO: 430 or SEQ ID NO: 592 through SEQ ID NO: 752, a biological equivalent thereof, or a fragment thereof. In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier. In yet other embodiments, the immunogenic composition further comprises one or more adjuvants. In a preferred embodiment, the polypeptide of the immunogenic composition is further defined as a Streptococcus pneumoniae polypeptide having 0, 1 or 2 transmembrane domains, a Streptococcus pneumoniae polypeptide having 3 or more transmembrane domains, a Streptococcus pneumoniae polypeptide having an outer membrane domain or a periplasm


Free Web Sudoku Puzzles.
Solve with your browser.
2       3     6  
  6         5   1
    4 8          
6     7         9
    5 9 8 3 6    
3         1     2
          5 7    
4   7         9  
  3     6       5
What is it?



Add Your Site · Terms Of Service · Privacy Policy


DISCLAIMER
Linkgrinder is a free service that searches the Internet and indexes all files found so that you may search quickly and easily for shared files. These files are created and made available individually by users whose identity we are not aware of and who we have no control over. In essence we function like a search engine tool; these files ARE NOT STORED OR SERVED BY OUR NETWORK. We are not responsible for any materials obtained by using our service. We do not monitor any of the contents of these files. These files may contain viruses, illegal materials, materials inappropriate for minors, offensive files and the like. BY USING OUR SERVICE, YOU ASSUME FULL RESPONSIBILITY FOR DOWNLOADING THESE MATERIALS AND WILL INDEMNIFY US FOR ANY DAMAGES THAT MAY BE INCURRED.

For More Specific Information VIEW OUR TERMS OF SERVICE.

Thank you and Enjoy!